A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

NCT07412704 · tracked via the Priya Life Science Belgium tracker

Sponsor

Bristol-Myers Squibb

Phase

Phase 1/2

Started

2026-09-15

Last updated

2026-09-22

Condition(s) studied

Arthritis, Rheumatoid

Investigational drug(s) / intervention(s)

BMS-986528

BMS-986528: Specified dose on specified days

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).

Eligibility

Sex

ALL

Min age

18 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria \- Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat. Exclusion Criteria * Juvenile arthritis or onset of inflammatory arthritis before age 18. * Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out. * Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment. * Other protocol-defined Inclusion/Exclusion criteria apply.

Primary outcome measure(s)

Number of participants with treatment-emergent adverse events (TEAEs) — Up to Week 54
Number of participants with Serious Adverse Events (SAEs) — Up to Week 54

Trial sites (39)

Facility	City	Region	Status
Local Institution - 0068	La Jolla	California	Not Yet Recruiting
Local Institution - 0070	Loma Linda	California	Not Yet Recruiting
Local Institution - 0069	Palo Alto	California	Not Yet Recruiting
Local Institution - 0050	Aurora	Colorado	Not Yet Recruiting
Colorado Blood Cancer Institute	Denver	Colorado	Recruiting
Local Institution - 0055	South Miami	Florida	Not Yet Recruiting
Local Institution - 0081	New York	New York	Not Yet Recruiting
Local Institution - 0079	New York	New York	Not Yet Recruiting
Local Institution - 0066	Portland	Oregon	Not Yet Recruiting
Local Institution - 0071	Philadelphia	Pennsylvania	Not Yet Recruiting
Local Institution - 0051	DeSoto	Texas	Withdrawn
Local Institution - 0048	Merksem	Flanders	Not Yet Recruiting
Local Institution - 0049	Leuven	Belgium	Not Yet Recruiting
Local Institution - 0083	Aparecida de Goiânia	Goiás	Not Yet Recruiting
Local Institution - 0033	Porto Alegre	Rio Grande do Sul	Not Yet Recruiting
Local Institution - 0082	Valinhos	São Paulo	Not Yet Recruiting
Local Institution - 0006	Beijing	Beijing Municipality	Not Yet Recruiting
Local Institution - 0080	Guangzhou	Guangdong	Not Yet Recruiting
Local Institution - 0010	Zhengzhou	Henan	Not Yet Recruiting
Local Institution - 0007	Nanchang	Jiangxi	Not Yet Recruiting
Local Institution - 0020	Shanghai	Shanghai Municipality	Not Yet Recruiting
Local Institution - 0001	Shanghai	Shanghai Municipality	Not Yet Recruiting
Local Institution - 0040	München	Bavaria	Not Yet Recruiting
Charité Research Organisation	Berlin	Germany	Recruiting
Local Institution - 0021	Cologne	Germany	Not Yet Recruiting
Local Institution - 0028	Herne	Germany	Not Yet Recruiting
St. Josef-Stift Sendenhorst	Sendenhorst	Germany	Recruiting
Local Institution - 0019	Rozzano	Milano	Not Yet Recruiting
Local Institution - 0017	Roma	Italy	Not Yet Recruiting
Local Institution - 0053	México	Mexico	Not Yet Recruiting
Local Institution - 0023	Józefów	Masovian Voivodeship	Not Yet Recruiting
CHUAC-Complejo Hospitalario Universitario A Coruña	A Coruña	A Coruña [La Coruña]	Recruiting
Hospital Universitario Reina Sofia	Córdoba	Spain	Recruiting
Universitaetsspital Bern - Inselspital	Bern	Switzerland	Recruiting
Local Institution - 0027	Geneva	Switzerland	Not Yet Recruiting
Local Institution - 0060	Ivano-Frankivsk	Ivano-Frankivsk Oblast	Not Yet Recruiting
Local Institution - 0063	Poltava	Poltava Oblast	Not Yet Recruiting
Local Institution - 0064	Kyiv	Ukraine	Not Yet Recruiting
Local Institution - 0061	Ternopil	Ukraine	Not Yet Recruiting

More Bristol-Myers Squibb trials in Belgium

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment Active, not recruiting

Pan Tumor Rollover Study Recruiting

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome Active, not recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) Recruiting

Other trials for the same condition

Anatomical Shoulder Domelock System Study Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07412704 on ClinicalTrials.gov ↗ ← All trials in Belgium